ArticleHeart and vessels2026
Risk stratification and determinants of cardiac recovery in hemodialysis patients with reduced ejection fraction.
Article in Heart and vessels, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Post-dialysis weight loss and cardiac recovery in hemodialysis: volume signal or causal determinant?Heart and vessels · 2026Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure and atherosclerotic comorbidities are common among patients receiving maintenance hemodialysis, yet therapeutic options remain limited. We aimed to clarify the long-term prognostic impact of reduced left ventricular ejection fraction (LVEF) and coronary heart disease (CHD) and explore potential determinants of cardiac recovery in this population. We retrospectively analyzed 310 hemodialysis patients who underwent coronary angiography for suspected CHD. Patients were stratified by baseline LVEF (< 40% vs. ≥ 40%) and the presence of CHD. Five-year mortality was compared between the groups, and associations with coronary intervention were examined. In a subset with follow-up echocardiography, changes in LVEF were analyzed in relation to medication use, coronary intervention, and relative post-dialysis body weight reduction. Patients with reduced LVEF had worse survival than those with normal LVEF (log-rank p = 0.001). Moreover, patients with reduced LVEF and concomitant CHD exhibited the poorest prognosis (log‑rank p = 0.001). Neither PCI nor medical therapy was associated with improvement in LVEF. In contrast, greater post-dialysis body weight reduction independently predicted attenuated recovery of cardiac function (HR 0.89; 95% CI 0.81-0.98; p = 0.018), with continuous analyses confirming an inverse relationship between ultrafiltration intensity and ΔLVEF. In hemodialysis patients with reduced LVEF, the coexistence of CHD requiring intervention identifies a high-risk phenotype, while cardiac recovery appears more strongly influenced by dialysis-related physiology than by conventional therapies. These findings highlight the need for personalized care strategies that integrate ischemic risk assessment with individualized dialysis management.
Indexed as
Identifiers
42115313What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.